Total
0
Shares
Clinuvel Pharmaceuticals (ASX:CUV) - CEO, Dr Philippe Wolgen - The Market Herald
CEO, Dr Philippe Wolgen
Source: The Photoprotection Channel
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Clinuvel Pharmaceuticals (CUV) has received approved registration from the Therapeutic Goods Administration (TGA) for its Scenesse drug
  • Scenesse is used in the prevention of skin irritation in adult patients with erythropoietic protoporphyria (EPP)
  • EPP is an inherited disorder which causes burns and internal damage to vessels when patients are exposed to light
  • Scenesse is a photo-protective drug which acts as an anti-oxidative, strengthens blood vessels and reduces swelling
  • It will be available as a prescription medication and will be administered by trained and accredited healthcare professional every two months
  • Clinuvel has ended the day 1.55 per cent in the red with shares trading for $21.61 each

Clinuvel Pharmaceuticals (CUV) has received approved registration from the Therapeutic Goods Administration (TGA) for its Scenesse drug.

Scenesse is used in the prevention of phototoxicity (skin irritation) in adult patients with erythropoietic protoporphyria (EPP).

EPP is an inherited disorder which causes burns and internal damage to vessels whenever patients are exposed to visible light, particularly sunlight or fluorescent lighting.

When exposed to light, patients may experience tingling, itching and burning of the skin. Continued exposure may make the skin become red and swollen.

While the hands and face are the most commonly affected areas, some people may also have complications in the liver or gallbladder.

As it's easier to remain indoors, those with EPP are traditionally deprived of social settings and outdoor activities.

This TGA approval of Scenesse is the first treatment approved for EPP patients in Australia.

Scenesse is a photo-protective drug that acts as an anti-oxidative, strengthens blood vessels and reduces swelling. It increases the levels of melanin in the skin and shields against UV radiation.

Studies have shown it reduces the severity and occurrence of phytotoxic reactions and increases the number of time patients can be exposed to light.

Scenesse will be registered in Australia for "the prevention in adult patients with EPP".

It will be available as a prescription medication and will be administered by a trained and accredited healthcare professional every two months.

"It is deeply satisfying to share with all involved that Scenesse has been approved to treat Australian EPP patients," Chief Scientific Officer Dr Dennis Wright commented.

"Our stepwise approach to regulatory engagement continues to be validated by today's news while we progress discussions in other regions where EPP patients lack access to treatment," he said.

Clinuvel has ended the day 1.55 per cent in the red with shares trading for $21.61 each in a $1.084 billion market cap.

CUV by the numbers
More From The Market Herald
Oil Search (ASX:OSH) - CFO & Acting CEO, Peter Fredricson - The Market Herald

" Oil Search (ASX:OSH) reports surge in revenue as prices recover

With the rise in oil and gas prices over the past few weeks, producers such as Oil Search (OSH) have been enjoying the
Lynas (ASX:LYC) - CEO, Amanda Lacaze - The Market Herald

" Lynas (ASX:LYC) posts record quarter as demand for rare earths drives up prices

Lynas Rare Earths (LYC) has reported a spike in sales as demand for its products continues.
Evolution Mining (ASX:EVN) - Executive Chairman, Jake Klein - The Market Herald

" Evolution Mining (ASX:EVN) raises $400m for Kundana purchase

Evolution Mining (EVN) has successfully completed its institutional placement and raised $400 million.
The Star Entertainment (ASX:SGR) drops bid for Crown (ASX:CWN) as royal commissions heat up

" The Star Entertainment (ASX:SGR) drops bid for Crown (ASX:CWN) as royal commissions heat up

Citing concerns over ongoing investigations, The Star Entertainment Group (SGR) has dropped its bid for Crown Resorts (CWN).